Table 2.
Motor milestones.
| Variable | The age at the initiation of treatment | Total (n = 310) | p- value | ||||
|---|---|---|---|---|---|---|---|
| Cohort A (n = 46) | Cohort B (n = 147) | Cohort C (n = 49) | Cohort D (n = 35) | Cohort E (n = 33) | |||
| Post-treatment head control (%) | 41 (89.1)a | 112 (76.2)a | 26 (53.1)b | 11 (31.4)bc | 4 (12.1)c | 194 (62.6) | <0.001 |
| Age at onset of treatment (months) | 3.00 (2.50–3.01) | 5.00 (4.00–5.50) | 7.00 (6.99–7.50) | 13.00 (12.00–14.50) | 35.00 (28.75–45.00) | ||
| Post-treatment supported sitting (%) | 36 (78.3)a | 91 (61.9)a | 19 (38.8)b | 2 (5.7)c | 0 (0.0)c | 148 (47.7) | <0.001 |
| Age at onset of treatment (months) | 3.00 (2.50–3.01) | 5.00 (4.00–5.01) | 7.00 (6.99–7.01) | 13.00 (12.99–13.01) | – | ||
| Post-treatment ability to rolling (%) | 33 (71.7)a | 71 (48.3)a | 10 (20.4)b | 0 (0.0)c | 0 (0.0)bc | 114 (36.8) | <0.001 |
| Age at onset of treatment (months) | 3.00 (2.50–3.01) | 5.00 (4.00–5.50) | 7.00 (6.99–7.13) | – | – | ||
| Post-treatment sitting for short periods without support (%) | 32 (69.6)a | 65 (44.2)b | 9 (18.4)c | 0 (0.0)c | 0 (0.0)c | 106 (34.2) | <0.001 |
| Age at onset of treatment (months) | 3.00 (2.50–3.01) | 5.00 (4.00–5.50) | 7.00 (6.00–7.01) | – | – | ||
| Post-treatment sitting for without support (%) | 27 (58.7)a | 51 (34.7)b | 7 (14.3)bc | 0 (0.0)c | 0 (0.0)c | 85 (27.4) | <0.001 |
| Age at onset of treatment (months) | 3.00 (2.50–3.01) | 5.00 (4.00–5.50) | 7.00 (6.99–7.01) | – | – | ||
| Post-treatment standing with support (%) | 13 (28.3)a | 21 (14.3)ab | 4 (8.2)ab | 0 (0.0)b | 0 (0.0)b | 38 (12.3) | <0.001 |
| Age at onset of treatment (months) | 3.00 (2.25–3.01) | 5.00 (4.00–5.01) | 7.00 (6.99–7.01) | – | – | ||
| Post-treatment standing without support (%) | 8 (17.4) | 8 (5.4) | 1 (2.0) | 0 (0.0) | 0 (0.0) | 17 (5.5) | 0.001 |
| Age at onset of treatment (months) | 3.00 (2.13–3.01) | 5.00 (4.63–5.75) | 7.00 (6.99–7.01) | – | – | ||
| Post-treatment walking (%) | 3 (6.5) | 5 (3.4) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 8 (2.6) | 0.175 |
| Age at onset of treatment (months) | 2.00 (1.99–2.00) | 5.00 (4.50–5.50) | – | – | – | ||
SMA, Spinal Muscular Atrophy. Statistically significant values are in bold. Values are shown as n (%). In post hoc comparisons the same superscripts indicate similarities among groups, while different superscripts indicate a statistically significant differences among groups. Values are shown as n (%), mean ± standard deviation, or median (1st-3rd quartiles).